In the present studies, we describe a new, strictly factordependent cell line (UCSD/AMLl) established from a patient with the syndrome of acute leukemia with high platelets and t(3;3)(q21;q26). These cells express megakaryocytic/platelet antigens and undergo primary proliferative responses and abnormal megakaryocytic differentiation in response to interleukin-6 (IL-6). Because IL-6 was recently shown to be an in vitro megakaryocyte maturation factor and an in vivo thrombopoietin?-" our findings suggest the ANLL syndrome associated with t(3;3)(q21;q26) involves cells with the ability to express megakaryocytic differentiation programs, and suggest IL-6 may play a role in the phenotypic manifestations of this disease. UCSD/AMLl cells also express antigens associated with multilineage hematopoietic progenitor cells, and display some characteristics of a second acute leukemia syndrome, CD7 positive acute leukemia with multilineage differentati~n.'~.'~
C characterized by specific clinical features and karyotype abnormalities,'.* suggesting that genetic lesions determine the pathogenesis or phenotypic manifestations of these syndromes. One such syndrome is characterized by acute nonlymphocytic leukemia (ANLL) presenting with high or normal platelet counts and chromosome deletions or translocations involving 3q2 1 and/or 3q26.'-7 Clinical findings in these patients are consistent with increased and abnormal megakaryo~ytopoiesis.~-~ Because genes involved in Fe metabolism (ie, transferrin and its receptor) are located in this area of chromosome 3, and Fe deficiency is characterized by increased platelet production, it has been suggested that these genes may somehow determine the clinical features of this syndrome. '.' In the present studies, we describe a new, strictly factordependent cell line (UCSD/AMLl) established from a patient with the syndrome of acute leukemia with high platelets and t(3;3)(q21;q26). These cells express megakaryocytic/platelet antigens and undergo primary proliferative responses and abnormal megakaryocytic differentiation in response to interleukin-6 (IL-6). Because IL-6 was recently shown to be an in vitro megakaryocyte maturation factor and an in vivo thrombopoietin?-" our findings suggest the ANLL syndrome associated with t(3;3)(q21;q26) involves cells with the ability to express megakaryocytic differentiation programs, and suggest IL-6 may play a role in the phenotypic manifestations of this disease. UCSD/AMLl cells also express antigens associated with multilineage hematopoietic progenitor cells, and display some characteristics of a second acute leukemia syndrome, CD7 positive acute leukemia with multilineage differentati~n.'~.'~
CASE HISTORY
The patient was a 73-year-old woman who presented to an outside hospital with progressive fatigue. She had no known exposure to cytotoxic drugs or radiation, and no prior history of a blood cell disorder. Her plasma Hb was 9.5 g/dL, platelet count 450,000/mm3, and white blood cell (WBC) count 6,800/mm3. The leukocyte differential showed 26% PMN, 9% bands, 9% metamyelocytes, 11% myelocytes, 28% lymphocytes, and 26 NRBCs/100 WBC. A bone marrow performed at an outlying hospital was hypercellular and showed normal to slightly increased megakaryocytes. Many of the megakaryocytes were small in size with a single large nucleus, or had When maintained in GM-CSF, a small percentage of cells form multinucleated megakaryocyte-like giant cells. Culture with GM-CSF combined with IL-6, but not with IL-6 alone, increased giant cell formation fourfold to sevenfold. IL-6 alone or in combination with GM-CSF increased expression of platelet-related antigens. In contrast, culture with phorbol ester induced formation of macrophage-like cells. UCSD/AMLI is the first human acute nonlymphocytic leukemia cell line established from a patient with an acute leukemia syndrome associated with a specific chromosome abnormality. 0 1990 by The American Society of Hematology. multiple separate nuclei. Blasts constituted 58% of the nonerythroid elements and ranged in size from small cells with a high nuclear/ cytoplasmic ratio, and indistinct nucleoli to cells of medium size with a moderate nuclear/cytoplasmic ratio and 1 to 3 nucleoli. There were no granules or Auer rods. Occasional dysplastic erythrocyte precursors showed nuclear/cytoplasmic dyssynchrony and multiple nuclei. A karyotype performed at an outside laboratory was 45,XX,-7,t(3;3)(q21;q26). Surface marker analysis, also performed at an outside laboratory, showed a mixture of cells expressing T-cell and granulocyte/monocyte related antigens (Diagnosis, Table  1 ). A stain for nuclear TdT was negative.
The patient developed progressive anemia over the next month, but her platelet count remained elevated. She was treated with daunorubicin, cytosine arabinoside, and high-dose cytosine arabinoside, but achieved only a brief remission. A repeat bone marrow was performed at relapse and showed greater than 70% small blasts with a T-cell phenotype (Relapse, Table 1 ). A karyotype performed at University of California, San Diego was again 45,XX,-7,t(3;3)(q21; q26) but, in addition, 4 of 12 metaphases analyzed demonstrated 45,XX, -7,t(3;3)(q21;q26), t( 12;22)(p13;ql2). She started on adriamycin/vincristine/prednisone therapy, but developed refractory leukemic meningitis and died.
MATERIALS AND METHODS
Bone marrow cells were obtained at relapse from induction therapy for ANLL. The cells were separated on Ficoll/ Hypaque and cultured at 5 x 105/mL in RPMI 1640 medium with 10% fetal bovine serum (FBS; Hyclone, Logan, UT) and 30 U/mL recombinant granulocyte-macrophage colony-stimulating factor Cell culture. Surface antigens on Ficoll/Hypaque separated bone marrow or the UCSD/AMLl cell line were detected by immunofluorescence staining using monoclonal antibodies (MoAbs) to the CD2, CD3, CD4, CD5, CD7, CD13, CD14, CD33, CD34, CD45 antigens (nomenclature is per reference 14) , and erythrocyte glycophorins as previously described." The platelet-associated CD41 (glycoprotein [GP] IIb/IIIa) antigen was detected using antiplatelet MoAb (DAKO Diagnostics, Santa Barbara, CA) or antibody 4F10 (reference 16; kindly provided by Dr Virgil Woods, University of California, San Diego). MoAbs to VLA-2 (12F1; reference 17) (platelet GPIa; CDw49b); platelet GPIb (CD42b) (P3; reference 18); and to platelet GPIV (CD36) (5F1; reference 19) were also provided by Dr Woods. Histochemical stains were performed using standard techniques as described.20 Nuclear TdT was detected by immunofluorescence staining using a specific heteroantiserum (Supertechs, Bethesda, MD). Southern blots were also performed using standard techniques,2' and immunoglobulin (Ig) and T-cell j3 receptor gene rearrangements assessed using probes to the Ig J, and T-cell j3 receptor constant regions (Oncor, Gaithersburg, MD). Placental DNA (Oncor) served as a germline control.
OVAL ET AL
Giemsa-banded karyotypes were obtained as previously described?2
Characterization of UCSDIAMLI cells.
Chromosomes from 12 separate metaphase cells from the relapsed marrow and 19 cells from the cell line were analyzed in detail. Recombinant erythropoietin and G-CSF were purchased from Amgen, Inc (Thousand Oaks, CA). Recombinant GM-CSF, IL-3, and IL-4 were kindly provided by Dr Stephen Gillis. Recombinant M-CSF (CSF-l), IL-5, and IL-6 were kindly provided by Dr Steven Clark (Genetics Institute, Cambridge, MA). Ultrapure IL-1 was purchased from Genzyme Corp (Boston, MA) and recombinant IL-2 from Cellular Products (Buffalo, NY). Erythropoietin, CSFs, and ILs were studied over a concentration range from 0.1 to 30 or 100 U/mL. COS cell supernatant containing recombinant IL-5 was also provided by Dr Clark, and studied at dilutions from 1:lO to 1:500.
Growth factor responses.
To determine responses to growth factors, cells were washed three times and plated into triplicate microtiter wells at 4 x 10S/mL in RPMI 1640 with 10% FBS and various concentrations of recombinant growth factors. At the fourth day of culture, the cells were pulsed with 'H-TdR (Amersham, Inc, Arlington Heights, IL) for 14 hours and harvested as previously described.23
To screen for synergy between growth factors, cells were washed and plated with the highest concentration of growth factors that failed to stimulate cell growth used alone, and complete GM-CSF, IL-3, or IL-6 dose-response curves ranging from 0.1 to 100 U/mL obtained. The following combinations were assessed: IL-3 doseresponse with 1 or 10 U/mL IL-4; IL-3 with 100 U/mL G-CSF; GM-CSF dose-response with 1 or 10 U/mL IL-4; IL-6 doseresponse with 1 or 10 U/mL IL-4. Cells were pulsed with 'H-TdR and harvested as described above.
To assess the abilities of growth factors to maintain continuous UCSD/AMLl cell growth, cells were washed three times and grown with FBS and 30 U/mL GM-CSF, 30 U/mL IL-3,30 U/mL IL-6, or 10 U/mL M-CSF. Viable cell counts were performed every 2 to 3 days for 3 weeks. To determine whether UCSD/AMLl cells survived in the absence of growth factors, cells were washed and plated at 4 x 10S/mL in RPMI 1640 with 10% FBS and observed for 2 weeks. At the 7th or 14th day of culture with media and FBS, an aliquot of cells was washed and resuspended in RPMI/FBS with 30 U/mL GM-CSF. These subcultures were then maintained for 2 weeks and viable cell counts determined every 2 to 3 days.
Induction of cellular differentiation. To assess macrophage or megakaryocytic differentiation, UCSD/AMLl cells were grown with GM-CSF, GM-CSF with 30 U/mL IL-6,30 U/mL IL-6 alone, lo-' mol/L tetradeconylphorbol-acetate (TPA; Sigma Chemicals, St Louis, MO), or TPA with 30 U/mL GM-CSF for 5 to 7 days. Morphology was assessed by an observer blinded to the incubation conditions using Wright-Giemsa-stained cytospins. Expression of the CD13, CD14, CD36, CD41, CD42b, and CD49b antigens was assessed after 5 days.
Growth factors.

RESULTS
After establishing the cell line in culture, the dominant cells were large blastlike cells with minimal granularity (Fig  1A) . However, rare giant cells with multiple, distinct nuclei were also present (Fig 1C) . Histochemical stains were strongly positive for acid phosphatase and nonspecific esterase, but negative for chloroacetate esterase. Surface marker analysis (Table 1) showed that UCSD/AMLl cells continued to express the CD7 T-cell-associated and CD34 primitive hematopoietic cell antigens, and remained TdT'. The cells also expressed the CD13, CD14, and CD33 myeloid antigens, and the platelet GPIIb/IIIa complex (CD41). Subpopulations expressed platelet GPIb (CD42b), the VLA2
B
The cell line karyotype was 45,XX,-7.t(3;3)(q21; q26),t( 12;22)(p13:ql2) in all metaphases examined. The t(3;3)(q21;q26) was apparently identical to that of the patient's cells at diagnosis and relapse, and the t( 12:22)(pI 3; q12) was identical to a subgroup of cells present at relapse only (Fig 2) .
To assess growth factor responses by UCSD/AMLI cells, log-phase cells were washed three times, plated with various concentrations of growth factors and FBS, and proliferation assessed by TdR uptake. As shown in Fig 3, UCSD/AMLl cells proliferated in response to IL-3, IL-4. IL-6, GM-CSF, and M-CSF, but showed no response to IL-I, IL-2, IL-5, or G-CSF (data not shown). The cells could be maintained as a factor-dependent cell line in GM-CSF, IL-6, or M-CSF with a doubling time of 48 to 72 hours, but could be continuously grown with IL-3 only with markedly reduced cellular viability. When GM-CSF was withdrawn, the cells ceased proliferating and 50% to 75% of cells died within 2 weeks. However, when the remaining cells were replated in GM-CSF. they rapidly recovered to their baseline growth rate (three experimen ts).
In other factor-dependent cell lines, growth factors synergize in stimulating cell gro~th.'~.'~ Because the cell line expressed the primitive CD34 antigen. we screened several growth factor combinations, which showed synergism in culture systems for putative early ("blast") by combining the highest concentration of a growth factor that did not stimulate cell growth with a complete doseresponse curve of a second growth factor. Combinations of 1 or IO U/mL IL-4 and GM-CSF or IL-6 showed no interaction. Similarly, G-CSF (100 U/mL) and IL-4 had no effect on IL-3-stimulated cell growth (not shown). or platelet GPla (CDw49b). and the platelet GPlV (CD36) antigens. Southern blots showed Ig and T-cell / 3 receptor genes to be in germline configuration (data not shown). Thus, the cell line retained characteristics of primitive hematopoietic cells expressing the CD7 and CD34 antigens and TdT, but also had characteristics consistent with GM and megakaryocytic cells. 
DISCUSSION
The new cell line described in the current studies retains properties of the acute leukemia with high-platelets
The cell line has a 3q21 translocation characteristic of this syndrome. Monosomy 7, present in the patient's cells and the cell line, and pre-existing myelodysplasia were also previously described as components of this ~yndrome.~.~.' Expression of G P IIb/IIIa, CD13, and CD14 by UCSD/ AMLl cells is similar to expression of platelet antigens by cells from a patient with ANLL and t( 1;3)(p36;q21).6 Thus, UCSD/AMLl cells appear to be the first cell line to preserve properties of an ANLL syndrome associated with a specific chromosomal translocation.
The original tumor cells and the cell line also share properties with multipotent CD7+ acute leukemias.12~13 The cell line retains CD7 expression and TdT positivity. In vitro, UCSD/AMLl cells form multinucleated giant cells consistent with abnormal megakaryocytes. Virtually identical cells were observed in short-term cultures of CD7+ acute leukemia cells.12 Several patients with CD7+ acute leukemia described in a previous report also had normal or high platelet counts,12 but lacked chromosome 3 abnormalities. Although UCSD/AMLl cells differentiate into both macrophage and megakaryocyte-like cells, thus far we have been unable to induce the broad range of lymphocyte and myeloid differentiation observed in short-term cultures of CD7+ acute leukemia cells.''
The ability of UCSD/AMLl cells to undergo aberrant megakaryocyte differentiation and proliferate in response to IL-6 may explain some features of the ANLL with highplatelets syndrome. The appearance of increased multinucleated giant cells after incubation with IL-6 and GM-CSF, but not IL-6 alone, suggests that UCSD/AMLl cells will be useful for studying cytokine interactions in this syndrome. In The expression of primitive hematopoietic cell, myeloid, and megakaryocytic antigens by UCSD/AMLl cells suggested these cells could undergo multilineage differentiation. When UCSD/AMLl cells were cultured with GM-CSF and TPA, they rapidly became adherent, and a few showed distinct spreading on plastic. The morphology of the cells became macrophage-like (Fig lB) , and expression of the CD14 antigen increased from 25% to 52% of cells (means of two experiments). Increased cellular adherence and spreading were also observed after long-term (2 weeks) culture with M-CSF. In the presence of GM-CSF and TPA, the number of multinucleated giant cells also increased slightly over cultures maintained in GM-CSF alone from 3% 1% of total cells to 8% 3% (means f SE; three experiments). Identical results were obtained when cells were grown for 5 days with TPA alone, but cell viabilities were decreased.
Because IL-6 was recently shown to be a maturation factor for megakaryocytes: surface antigen expression and morphology of UCSD/AMLl cells were also examined after culture with IL-6. After 5 days of culture with GM-CSF and 30 U/mL IL-6, the number of multinucleated giant cells increased fourfold to sevenfold (18% f 6%; N = 3), but did not increase in the presence of IL-6 alone. In contrast, immunofluorescence staining after exposure to IL-6 (not shown) or IL-6 with GM-CSF showed increased expression of three platelet-associated antigens (platelet GPIIb/IIIa complex, platelet GPIa, and platelet GPIV) (Fig 4) . When cells were gated according to low-angle light scatter, increased platelet antigen expression was observed in cells of both intermediate and large size, suggesting the increase in platelet antigen expression was not restricted to multinucleated giant cells. Thus, UCSD/AMLl cells showed evidence for both macrophage and megakaryocytic differentiation. T(3;3)(o21;a26) 1373 future studies, it will also be important to examine effects of IL-6 on proliferation and differentiation of primary tumor cells from patients with t(3;3)(q21;q26).
Whether genes involved in the t(3;3)(q21;q26) induce leukemic transformation or alter its phenotypic manifestations is a t present unclear. Although it has been postulated that genes involved in cellular Fe metabolism may be involved in these translocations,' Southern blots of DNA from the UCSD/AMLl cells showed no gross rearrangements of the transferrin receptor gene (data not shown). The establishment of the UCSD/AMLl cell line should allow cloning and characterization of the genes involved in this translocation.
In short-term culture, UCSD/AMLI cells respond to a wide variety of growth factors, including IL-6, IL-4, and M-CSF, which may stimulate primitive normal marrow ("blast") progenitor^,^^^^^ but do not directly stimulate growth of normal G M progenitors2' or most ANLL cells in vitro. 29 The extent to which human factor-dependent leukemia cell lines reflect growth factor responses by primary ANLL cells is unclear. It is possible that continuous exposure to growth factors in vitro selects for cells or mutations allowing factor-dependent growth in the same way culture with FBS and media alone selects for relatively factor-independent cells. UCSD/AMLl cells contain a t(12;22) present in only a subpopulation of the patients' cells at relapse, indicating selection in culture for this tumor cell population. The broad range of growth factor responses displayed by these cells could give these cells a proliferative advantage in vivo over their normal counterparts.
A subpopulation of UCSD/AMLl cells survives growth factor deprivation for extended periods. These results differ from studies using murine factor-dependent cells that require growth factors, such as IL-3, for survival and rapidly die when growth factors are ~i t h d r a w n .~' We are currently evaluating whether growth factors contained in FBS may partially maintain UCSD/AMLl cell viability. This property of the cell line may allow detailed study of the nonproliferating (Go) state in factor-dependent human myeloid leukemia cells.
UCSD/AMLI represent a valuable addition to the limited roster of available factor-dependent, human ANLL cell lines. Establishment of cell lines from patients with other acute leukemia syndromes may provide similar insights into the pathophysiology of these acute leukemia syndromes, and the eventual definition of the roles chromosome translocations play in the establishment and maintenance of acute leukemia.
